Navigation Links
Berkery Noyes Releases 2009 Pharma and Healthcare Information Merger & Acquisition Trends
Date:2/10/2010

NEW YORK, Feb. 10 /PRNewswire/ -- Revenue multiples in the Pharma and Healthcare Information and Technology market experienced a significant half-to-half gain as exhibited by the 81% increase in the median enterprise value/revenue multiple from 1.1 in 1st Half 2009 to 2.0 in 2nd Half 2009. This rise brings the median enterprise value/revenue multiple within 76% of its peak in 1st Half 2008.

(Photo: http://www.newscom.com/cgi-bin/prnh/20100210/NY53156 )

2nd Half 2009 exhibited an increase in both aggregate volume and aggregate value, versus 1st Half 2009. Half-to-half, aggregate value increased 150% from approximately $2 billion to $5 billion, and aggregate volume increased by 15% from 86 deals to 99. The 2nd Half 2009 level of activity, as measured by aggregate value and aggregate volume, is on par with 2nd Half 2007, and slightly below the peak of activity in 1st Half 2008.

For the full year 2009, The Pharma and Healthcare Information and Technology market exhibited negative growth with declines in both aggregate value and aggregate volume of transactions. Total transaction volume declined by 12% from 209 deals in 2008 to 184 in 2009. Aggregate value declined by 16% from $9.43 billion in 2008 to $7.89 billion in 2009.

The largest transaction in the Pharma and Healthcare Information and Technology market in 2009, and going back to 2007, was TPG Capital and CPP Investment Board's proposed acquisition of IMS Health, Inc. for $4.01 billion, announced on November 5th.

Please note that for evaluating aggregate transaction values, value represents total consideration paid by acquirer. For multiples Berkery Noyes uses enterprise values (EV) that normalize values where less than 100% of a company is being acquired or has net debt.

To read the free four page report Click Here (http://berkerynoyes.com/visit/BNCFY09Healthcare.aspx)

Berkery Noyes provides skilled transaction management to publicly traded and privately held businesses and private equity groups in both sell-side and buy-side mergers and acquisitions. We have managed transactions ranging from several million to more than four billion dollars in value, with an emphasis on mid market transactions of $10 million to $500 million in enterprise value.

Our clients include private companies seeking a buyer, most of the major international information companies, and private equity firms who use the firm's expertise in locating, analyzing and negotiating with acquisition candidates and in managing divestitures. The firm operates with a staff of thirty professionals serving the information industry.

For more information, visit www.berkerynoyes.com.

SOURCE Berkery Noyes

RELATED LINKS
http://www.berkerynoyes.com

'/>"/>

SOURCE Berkery Noyes
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
2. SpectraScience Releases Shareholder Newsletter
3. Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics
4. Lilly Releases Latest Value of Medicine Resource Guide About Key Issues Facing the Pharmaceutical Industry
5. ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
8. AdvaMed Releases New Survey Results on DTC Campaigns
9. CEL-SCI Corporation Releases Letter to Shareholders
10. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
11. Velos, Inc. Releases Software to Support Cancer Centers With New Workflow and Content for NCI Clinical Trials Reporting Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
(Date:4/18/2017)... MINNEAPOLIS , April 18, 2017 Cogentix ... focused on providing the Urology, Uro/Gyn and Gynecology markets ... for the first quarter ended March 31, 2017 after ... The Company will host a conference call ... day on Tuesday, May 2, 2017 at 4:30 p.m. ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., developer ... series to be presented at the 2017 National Kidney ... today and continues through April 22. Physicians will present ... used to assess risk for acute kidney injury (AKI) ... failure (ADHF). Elevated levels of TIMP-2 ...
Breaking Medicine Technology:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... Phytomer USA ... As a Phytomer Account Manager, Smith’s role is to provide excellent customer ... that make up The Phytomer Group. Smith comes to Phytomer with a wealth of ...
(Date:4/28/2017)... ... April 28, 2017 , ... The National Campaign to ... the Access to Contraception for Women Servicemembers and Dependents Act of 2017. The ... will help to ensure that all members of the Armed Forces receive high ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of New Jersey ... “A” and its outlook as “stable.” At the same time, the ratings agency cautioned ... recent years, dip below “capital adequacy” thresholds required for its strong rating. , “Horizon ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Radiology Business Management ... officers for 2017-2018. The annual board election process has been in place since the ... , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... liability could substantially improve drug safety and minimize the cost of development. In ... ion channel inhibition using cell lines and for cardiac toxicity using induced pluripotent ...
Breaking Medicine News(10 mins):